NEW YORK (Thomson Financial) - Omrix Biopharmaceuticals Inc. Monday reported
third-quarter income of $3.7 million, or 21 cents a share, beating the mean
estimate of analysts polled by Thomson Financial for profit of 13 cents a share.
Revenue fell 14% to $15.8 million from $18.3 million a year earlier.
For the full-year, Omrix raised its product sales outlook to $46 million to
$49 million from $42 million to $47 million.
Shares of Omrix closed at $34.90 on Friday.
Christie Rizk
cr/pc
COPYRIGHT
Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|